DDX41 and chronic myelogenous leukemia, BCR-ABL1 positive: Since the CML by xenoantigen- or GP-specific Abs relies on the same mechanism of complement activation it is likely that xenoantigen-specific antibodies also reduce the effective dose in vivo similarly to GP-specific antibody neutralization.